Rennova Health Announces Formation of Scientific Advisory Committee

Download as PDF

First Meeting Held of Thought Leaders in Clinical Diagnostics and Medicine

WEST PALM BEACH, Fla.-- Rennova Health, Inc. (NASDAQ:RNVA) (NASDAQ:RNVAW), which owns and operates a diverse family of healthcare companies, announces the formation of a Scientific Advisory Committee. The Committee, which was appointed by the Company’s board of directors, is comprised of Chairman Thomas Mendolia, D.O., George Lundberg, M.D., Bernard Manz, Ph.D., Georg Manz, Paul Billings, M.D., Kamran Ajami, M.D., Christopher Mason, Ph.D. and Asad Zaidi.

"Our new Scientific Advisory Committee, which held its first meeting earlier this month, includes esteemed professionals with impressive backgrounds in medicine, as well as leadership positions at academic institutions worldwide and countless medical discoveries that impacted their fields of expertise, from immunology to genomic medicine," said Seamus Lagan, CEO of Rennova Health, Inc. "Their collective years of medical expertise and business success will prove invaluable as Rennova Health widens its reach to include more diagnostic tests, including genomic diagnostics, diabetes, esoteric and direct access testing."

Dr. Thomas Mendolia

Dr. Mendolia is a retired gastroenterologist and co-founder of Medytox Solutions, Inc. He was in clinical practice for 29 years, including 17 years in private practice at Tri-County Gastroenterology in Elkin, N.C. He also ran Northwest Piedmont Clinical Research, where he oversaw 40 clinical trials mainly focused on compounds related to gastrointestinal diseases. After retiring from medical practice, he became the medical director of Prestige Surgical Centers across Florida and New Jersey. Dr. Mendolia received his medical degree from New York College of Osteopathic Medicine.

Dr. George Lundberg

Dr. Lundberg is president and chair of the board of directors of The Lundberg Institute, a consulting professor at Stanford University and editor-at-large for Medscape from WebMD. Dr. Lundberg has more than 30 years of experience as editor-in-chief of JAMA (The Journal of the American Medical Association), 10 AMA specialty journals, AM News, Medscape, The Medscape Journal, e-Medicine from Web MD and MedPage Today from Everyday Health. In 1995 he was called the medical Internet "pioneer." He served as president of the American Society for Clinical Pathology, professor of pathology and associate director of laboratories at the Los Angeles County/USC Medical Center for 10 years, and was the professor and chair of pathology at the University of California, Davis for five years. Dr. Lundberg holds earned and honorary degrees from North Park College, Baylor University, the University of Alabama (Birmingham and Tuscaloosa), the State University of New York, Syracuse, Thomas Jefferson University and the Medical College of Ohio. Dr. Lundberg also is a Vietnam War veteran.

Dr. Bernhard Manz

Bernhard Manz, Ph.D., LDN developed DrySpot, the first urinary spot test for neurotransmitters six years ago. Dr. Manz has published more than 100 scientific papers related to his fields of interest and is considered an expert in neurotransmitter testing. He has the most comprehensive research to date on this testing modality.

Georg Manz

Georg Manz has a background in immunology and immunoassay development. He worked with Dr. Bernhard Manz on the development and the implementation of the DrySpot technology. Since 2012 Georg has been general manager of Labor Diagnostika Nord (LDN), and since 2015 has served as CEO of Rocky Mountain Diagnostics. In the last two years, he raised over €500,000 in governmental grants to promote research and development in field of neurotransmitter testing. In 2014 LDN successfully applied for an AOAC approval for its histamine test for food control. Georg holds an MSc degree in biomedical chemistry from the Johannes Gutenberg University of Mainz in Germany.

Dr. Paul Billings

Dr. Billings is a nationally recognized author, lecturer, consultant, professor and thought leader in the field of genomic medicine and has served as a director of CollabRx, Inc. since 2014. A board-certified internist and clinical geneticist, Dr. Billings' career has been devoted to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as chief medical officer of Life Technologies, Inc. He was co-founder and first medical director of the Cordblood Registry, Inc., past senior physician and senior vice president of Laboratory Corporation of America, Inc. (LabCorp), co-founder and past director of Omicia, Inc., founder and executive vice president of GeneSage, Inc., and past director of Ancestry.com, Inc. Dr. Billings currently serves on the Scientific Advisory Board of the U.S. Food and Drug Administration, the Genomic Medicine Advisory Committee at the Department of Veterans Affairs and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Dr. Billings holds a B.A. from the University of California San Diego, an M.D. from Harvard Medical School and a Ph.D. in immunology from Harvard University.

Dr. Kamran Ajami

Dr. Kamran Ajami is a surgical pathologist with sub-specialties in gynecology, breast pathology and neuropathology. He has 22 years of experience in cancer diagnosis and moved from an academic position at Harvard Medical School to his current position serving as the market lead of South Florida's division of HCA hospitals and chairman and medical director of Westside Regional Medical Center and Plantation General Hospital. Dr. Ajami serves as the CEO of Cytopathology Associates, the company that employs the medical directors working at some of the Rennova Health Laboratories. He has vast experience in medical malpractice and healthcare-associated law.

Dr. Christopher Mason

Dr. Christopher Mason is an associate professor of computational genomics and neuroscience in the department of physiology and biophysics at the Feil Family Brain and Mind Research Institute, and the Institute for Computational Biomedicine at Weill Cornell Medical College in New York City. Dr. Mason develops and applies advanced techniques in genomics technology and integrative bioinformatics to discern the functional elements of the human genome and how they are disturbed in cancer and neuro-development, as well as how they respond to severe environmental pressures. Dr. Mason holds bachelor's degrees in genetics and in biochemistry from the University of Wisconsin-Madison, and performed his graduate thesis in Kevin White's Laboratory at Yale University, building custom gene expression microarrays and developing bioinformatics tools. He then did two simultaneous post-doctoral fellowships at Yale, one in Matthew State's Laboratory on Neurogenetics at Yale Medical School focusing on genetic mutations and genetic variations that lead to neuro-psychiatric disorders and brain malformations, and the other as a Fellow of Genomics, Ethics and Law at Yale Law School's Information Society Project, where he worked on gene patents, eventually leading to his appearance as an expert witness in the U.S. Supreme Court case of Myriad v. AMP in 2013.

Asad Zaidi

Asad R. Zaidi, president and CEO of Epinex Diagnostics, Inc., is a biochemist and biomedical engineer. Mr. Zaidi has been involved since 1973 with the development of heart valves, artificial coronary arteries, membrane oxygenators, dialyzers and various in vitro diagnostic and biomedical devices. His experience spans the growth of biomedical devices in companies such as Shiley (Pfizer), C.R. Bard, Mitral Medical, Bicer Medical and Medtronic. He has been responsible for licensing and transferring medical device manufacturing technology from Latin America to Canada and England. His areas of expertise range from product development to patenting and production. He has written and assisted in FDA submissions of 510(k) applications, investigational device exemptions and premarket approval authorizations. He received his B.S. degree with honors from University of California, Irvine.

About Rennova Health, Inc.

Rennova Health, Inc. (NASDAQ: RNVA) provides industry-leading diagnostics and supportive software solutions to healthcare providers, delivering an efficient, effective patient experience and superior clinical outcome. Through an ever-expanding group of strategic brands that work in unison to empower customers, we are creating the next generation of healthcare. For more information about Rennova Health, Inc., visit www.rennovahealth.com.

Rennova Health:
Sebastien Sainsbury, 561-666-9818
ssainsbury@rennovahealth.com
or
Investors:
LHA
Kim Golodetz, 212-838-3777
Kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
Bvoss@lhai.com

Source: Rennova Health, Inc.

Released February 9, 2016